Patricia Inácio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Oral NNI-351 Awarded Orphan Drug Status by FDA

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NeuroNascent’s NNI-351 for the treatment of fragile X syndrome. NNI-351, given orally, is able to penetrate the brain, where it has been shown to boost the proliferation and growth of immature progenitor cells into mature…

Gaboxadol in Combo Therapy for Fragile X Worth Pursuing: Healx

Healx has entered into an exclusive licensing agreement with Ovid Therapeutics to develop and commercialize gaboxadol in a potential combination treatment for fragile X syndrome and other disorders. The announcement follows Ovid’s decision to discontinue the development of gaboxadol (previously called OV101), despite it being deemed safe and well-tolerated in…

Quris Planning AI-powered Clinical Trial in 2022

A candidate therapy for fragile X syndrome — developed using Quris’ bio-artificial intelligence clinical prediction platform — will enter clinical trials in 2022, the company announced. Quris is using the power of artificial intelligence (AI)  combined with a “patients-on-a-chip” platform to predict the safety and potential effectiveness of therapeutic…

Nova Seeks Orphan Drug Status in US for Psilocybin, Hallucinogenic Therapy

Nova Mentis has filed an application for orphan drug designation with the U.S. Food and Drug Administration (FDA) for psilocybin, its investigational psychedelic therapy for fragile X syndrome. Recently, psilocybin received orphan drug designation from the European Medicines Agency (EMA), which offers financial incentives for potential rare disease treatments. Nova also…

FDA OKs Phase 2 Trial Design for Xanamem

The U.S. Food and Drug Administration (FDA) has given positive feedback to Actinogen’s pre-investigational new drug (pre-IND) submission regarding Xanamem, its experimental oral therapy for fragile X syndrome. In a written response following a pre-IND meeting with Actinogen, the FDA agreed the data gathered and the proposed trial design…